[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Steiner H, Peschel R, Bartsch G: Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary? BJU Int; 2008 Aug;102(3):310-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary?
  • OBJECTIVE: To evaluate the long-term oncological outcome in selected patients treated for nonseminomatous germ cell tumours (NSGCT) with a retroperitoneal lymph node dissection after chemotherapy (pcRPLND) and not using the full bilateral template.
  • PATIENTS AND METHODS: From 1988 to 2005, 102 patients with retroperitoneal stage II NSGCT, who at initial presentation had metastases in the primary retroperitoneal site only, had pcRPLND within a restricted template, whether computed tomography showed complete or incomplete remission.
  • Only the latter was retrocaval, above the level of the inferior mesenteric artery within the boundaries of a full bilateral RPLND.
  • This patient had had left unilateral template dissection after chemotherapy for IIC disease which was restricted to the para-aortic nodes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Node Excision / standards. Neoplasms, Germ Cell and Embryonal / drug therapy. Retroperitoneal Neoplasms / secondary. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Ejaculation. Humans. Lymph Nodes. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325053.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Xue H, Field CJ, Sawyer MB, Dieleman LA, Baracos VE: Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy. Br J Cancer; 2009 May 19;100(10):1581-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.
  • Infectious complications are a major cause of morbidity and mortality from dose-intensive cancer chemotherapy.
  • In spite of the importance of intestinal bacteria translocation in these infections, information about the effect of high-dose chemotherapy on gut mucosal immunity is minimal.
  • We studied prophylactic ciprofloxacin (Cipro) treatment on irinotecan (CPT-11) toxicity and host immunity in rats bearing Ward colon tumour.
  • Cipro abolished chemotherapy-related mortality, which was 45% in animals that were not treated with Cipro.
  • Seven days after CPT-11, splenocytes were unable to proliferate (stimulation index=0.10+/-0.02) and produce proliferative and inflammatory cytokines (i.e., Interleukin (IL)-2, interferon-gamma (IFN-gamma), tumour necrosis factor-alpha (TNF-alpha) IL-1beta, IL-6) on mitogen stimulation in vitro (P<0.05 vs controls), whereas mesenteric lymph node (MLN) cells showed a hyper-proliferative response and a hyper-production of pro-inflammatory cytokines on mitogen stimulation.
  • This suggests compartmentalised effects by CPT-11 chemotherapy on systemic and intestinal immunity.
  • [MeSH-major] Antibiotic Prophylaxis / methods. Camptothecin / analogs & derivatives. Carcinoma / drug therapy. Ciprofloxacin / therapeutic use. Colorectal Neoplasms / drug therapy. Immunity, Mucosal / drug effects. Intestinal Mucosa / drug effects
  • [MeSH-minor] Animals. Anti-Infective Agents / pharmacology. Anti-Infective Agents / therapeutic use. Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Agents, Phytogenic / therapeutic use. Diarrhea / chemically induced. Diarrhea / complications. Female. Lymphatic Metastasis. Neoplasm Transplantation. Rats. Rats, Inbred F344. Spleen / drug effects. Spleen / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3270-4 [9699654.001]
  • [Cites] Drugs. 1996 Oct;52(4):606-23 [8891470.001]
  • [Cites] J Surg Res. 1998 Sep;79(1):39-46 [9735238.001]
  • [Cites] J Immunol Methods. 2004 Oct;293(1-2):127-42 [15541283.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1029:9-15 [15681738.001]
  • [Cites] Ann Intern Med. 2005 Jun 21;142(12 Pt 1):979-95 [15968013.001]
  • [Cites] J Nutr Biochem. 2006 Jan;17(1):37-44 [16098728.001]
  • [Cites] Infection. 2005 Dec;33 Suppl 2:55-70 [16518713.001]
  • [Cites] Clin Immunol. 2006 Apr;119(1):110-9 [16458073.001]
  • [Cites] Int Immunol. 2006 Jun;18(6):941-9 [16636014.001]
  • [Cites] Clin Immunol. 2006 Sep;120(3):239-46 [16581297.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1743-51 [16977651.001]
  • [Cites] Br J Haematol. 2000 Jan;108(1):105-15 [10651733.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2000 Sep;31(3):291-9 [10997375.001]
  • [Cites] Science. 2000 Oct 6;290(5489):97-100 [11021807.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Feb;163(2):316-21 [11179099.001]
  • [Cites] Oncologist. 2001;6(1):66-80 [11161230.001]
  • [Cites] Shock. 2001 Aug;16(2):83-96 [11508871.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3801-7 [11559717.001]
  • [Cites] Shock. 2001 Dec;16(6):454-8 [11770044.001]
  • [Cites] Vet Immunol Immunopathol. 2002 Sep 10;87(3-4):109-21 [12072225.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5778-84 [12384538.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Dec 1;166(11):1417-8 [12450929.001]
  • [Cites] N Engl J Med. 2003 Jan 9;348(2):138-50 [12519925.001]
  • [Cites] Lancet Infect Dis. 2003 Jun;3(6):359-71 [12781508.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Sep;18(9):1095-100 [12911669.001]
  • [Cites] Hematology. 2003 Oct;8(5):303-11 [14530172.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2851-9 [15102694.001]
  • [Cites] Cancer Immunol Immunother. 2004 Aug;53(8):740-7 [15133630.001]
  • [Cites] Cancer. 1976 Feb;37(2 Suppl):1058-69 [766953.001]
  • [Cites] J Clin Invest. 1986 Mar;77(3):841-9 [3005367.001]
  • [Cites] Antimicrob Agents Chemother. 1986 Feb;29(2):337-8 [2940967.001]
  • [Cites] J Antimicrob Chemother. 1986 Jun;17(6):811-4 [3090010.001]
  • [Cites] Immunol Lett. 1988 Nov;19(3):183-91 [3069706.001]
  • [Cites] Clin Immunol Immunopathol. 1990 Jan;54(1):126-33 [2403487.001]
  • [Cites] Adv Exp Med Biol. 1990;256:549-56 [2183565.001]
  • [Cites] Clin Exp Immunol. 1991 Aug;85(2):331-4 [1864014.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):285-91 [1376185.001]
  • [Cites] Eur J Immunol. 1992 Jul;22(7):1843-50 [1378021.001]
  • [Cites] Arch Surg. 1993 Jan;128(1):89-94; discussion 94-5 [8418786.001]
  • [Cites] Immunology. 1993 Jul;79(3):479-84 [8406575.001]
  • [Cites] Immunopharmacology. 1994 Mar-Apr;27(2):155-64 [8014029.001]
  • [Cites] J Surg Res. 1994 Jun;56(6):579-85 [8015314.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2221-8 [7919339.001]
  • [Cites] Chest. 1997 Jul;112(1):235-43 [9228382.001]
  • [Cites] Exp Hematol. 1997 Aug;25(9):992-1004 [9257813.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3789-98 [9345067.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 1997;45(4):277-84 [9523001.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7146-54 [18056195.001]
  • [Cites] J Exp Med. 1994 Dec 1;180(6):2401-6 [7525854.001]
  • [Cites] J Immunol. 1995 Feb 15;154(4):1675-83 [7836751.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):482-90; discussion 490-2 [7574928.001]
  • [Cites] Biotherapy. 1996;8(3-4):243-9 [8813336.001]
  • [Cites] Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):72-8 [9726096.001]
  • (PMID = 19401694.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antineoplastic Agents, Phytogenic; 5E8K9I0O4U / Ciprofloxacin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2696758
  •  go-up   go-down


3. Tanoue Y, Tanaka N, Suzuki Y, Hata S, Yokota A: A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism. World J Gastroenterol; 2009 Jan 14;15(2):248-51
Genetic Alliance. consumer health - Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism.
  • We report a case of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein (IMV) tumor embolism.
  • We performed colonoscopy, computed tomography and positron emission tomography, which disclosed sigmoid colon cancer with IMV tumor embolism.
  • She underwent sigmoidectomy and lymph node dissection.
  • The tumor was diagnosed as endocrine cell carcinoma (type 4, pSS, med, INFalpha, v3, n1, stage IIIb).
  • She was treated with chemotherapy of cisplatin (CDDP) + irinotecan (CPT11).
  • This case highlights the aggressiveness of endocrine cell carcinoma with tumor embolism, and it is essential to establish an accurate diagnosis and effective treatment.
  • [MeSH-minor] Aged. Female. Humans. Mesenteric Veins / pathology. Neoplasm Invasiveness / pathology. Neoplastic Cells, Circulating / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1351-5 [10604732.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Gastric Cancer. 2003;6(4):203-9 [14716513.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Cancer Res. 1983 May;43(5):2088-93 [6187442.001]
  • [Cites] Surg Today. 2007;37(11):989-94 [17952533.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):315-21 [1847579.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Pathol Int. 1995 Aug;45(8):605-9 [7496507.001]
  • [Cites] South Med J. 1996 Sep;89(9):921-4 [8790320.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):135-40 [2293859.001]
  • (PMID = 19132778.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2653316
  •  go-up   go-down


Advertisement
4. Boghossian V, Owen ID, Nuli B, Xiao PQ: Neuroendocrine (Merkel cell) carcinoma of the retroperitoneum with no identifiable primary site. World J Surg Oncol; 2007;5:117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Neuroendocrine carcinoma is an aggressive neoplasm that mainly affects elderly Caucasians and typically arises in sun-exposed areas of the skin.
  • Pathological and immunohistochemical analysis of the transabdominal CT-guided biopsy specimen revealed tissue consistent with neuroendocrine carcinoma.
  • The patient underwent exploratory laparotomy and the mass was successfully excised along with an associated mesenteric lymph node.
  • First, the retroperitoneal mass could be a massively enlarged lymph node where precursor cells became neoplastic.
  • This would be consistent with a presumptive diagnosis of primary nodal disease.
  • Since Merkel cell precursors have never been identified within lymph nodes, the latter theory seems more befitting.
  • Moreover, metastasis to the retroperitoneal lymph nodes has been reported as relatively common when compared to other sites such as liver, bone, brain and skin.
  • CONCLUSION: Wide local excision of the primary tumor is the surgical treatment of choice for localized disease.
  • We propose that further studies are needed to elucidate the true efficacy of chemotherapy in conventional as well as unconventional patients with neuroendocrine carcinoma.
  • [MeSH-major] Carcinoma, Merkel Cell / secondary. Carcinoma, Neuroendocrine / secondary. Lymph Nodes / pathology. Neoplasms, Unknown Primary / pathology. Retroperitoneal Neoplasms / secondary
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Laparotomy / methods. Male. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2000 Jan-Feb;7(1):72-83 [10740663.001]
  • [Cites] Australas J Dermatol. 2006 Aug;47(3):160-5 [16866994.001]
  • [Cites] Am Surg. 2001 Oct;67(10):943-7 [11603550.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115 Suppl:S68-78 [11993692.001]
  • [Cites] Plast Reconstr Surg. 2002 Oct;110(5):1259-65 [12360064.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):515-7 [12789943.001]
  • [Cites] Isr Med Assoc J. 2003 Jun;5(6):450-1 [12841023.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(5):609-26 [3092460.001]
  • [Cites] Ann Surg. 1988 Feb;207(2):201-7 [3277546.001]
  • [Cites] J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):254-6 [2170468.001]
  • [Cites] Am J Surg Pathol. 1992 Jul;16(7):658-66 [1530107.001]
  • [Cites] J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):143-56 [8335732.001]
  • [Cites] Am J Otolaryngol. 1997 Jan-Feb;18(1):55-65 [9006679.001]
  • [Cites] Semin Cutan Med Surg. 1998 Jun;17(2):114-32 [9669605.001]
  • [Cites] J Am Acad Dermatol. 1998 Nov;39(5 Pt 2):882-7 [9810922.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):856-8 [15557979.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2300-9 [15800320.001]
  • [Cites] ANZ J Surg. 2005 May;75(5):275-81 [15932436.001]
  • [Cites] J Cutan Med Surg. 2000 Oct;4(4):186-95 [11231196.001]
  • (PMID = 17949500.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2117014
  •  go-up   go-down


5. Ogata Y, Torigoe S, Matono K, Sasatomi T, Ishibashi N, Shida S, Ohkita A, Mizobe T, Ikeda S, Ogou S, Ozasa H, Shirouzu K: Prognostic factors after potentially curative resection in stage II or III colon cancer. Kurume Med J; 2005;52(3):67-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is important to identify factors that are predictive of outcome after a curative resection in colon cancer in order to optimize adjuvant therapy.
  • These patients received no preoperative chemotherapy, immunotherapy or radiotherapy.
  • Postoperative adjuvant chemotherapy using oral fluoropyrimidines was performed in 127 patients, and the other 63 patients underwent surgery alone.
  • The univariate analysis revealed that invasion to adjacent organs, N1-2, positive mesenteric lymph node metastasis (MLN+), lymphatic permeation (ly)1-3, venous invasion (v)1-3, and v2-3 were each significant factors indicating worse disease-free survival, and that N1-2, MLN+, ly1-3, v1-3 and v2-3 were each significant factors for worse overall survival.
  • In conclusion, stage II or III colon cancer patients positive for mesenteric lymph node metastasis or for venous invasion have a greater risk of recurrence and death after potentially curative resection.
  • Postoperative adjuvant chemotherapy using oral fluoropyrimidines did not significantly reduce the risk of recurrence and death in these patients.
  • More effective adjuvant chemotherapy than oral fluoropyrimidine should be considered, especially in such high-risk patients.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422171.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


6. Yamaguchi T, Takahashi H, Kagawa R, Takeda R, Sakata S, Nishizaki D, Takamatsu T, Iwasa Y: Surgical resection combined with CHOP chemotherapy plus rituximab for a patient with advanced mesenteric diffuse large B cell lymphoma. Hepatogastroenterology; 2008 May-Jun;55(84):891-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection combined with CHOP chemotherapy plus rituximab for a patient with advanced mesenteric diffuse large B cell lymphoma.
  • Herein is described a mesenteric diffuse large B cell lymphoma (DLBCL) case with a bulky mass which had achieved a complete remission by the combination therapy of a surgical resection and the CHOP chemotherapy with rituximab.
  • Abdominal US revealed lymph node swellings at the paraaortic region.
  • After the operation, it was determined to be Stage IV DLBCL and the chemotherapy based on the R-CHOP regimen was performed.
  • During the chemotherapy, he was confirmed to have achieved a complete remission.
  • The present case is a rare case in which a Stage IV mesenteric DLBCL with extensive bulky masses had a favorable prognosis.
  • Stage IV mesenteric DLBCLs with extensive bulky masses are thought to be the indication for the combination therapy of surgical resection and multiagent chemotherapy with rituximab.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery. Mesentery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Chemotherapy, Adjuvant. Colon, Sigmoid / pathology. Colon, Sigmoid / surgery. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Ileum / pathology. Ileum / surgery. Lymph Nodes / pathology. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Staging. Prednisolone / administration & dosage. Rituximab. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705290.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


7. Ogata Y, Torigoe S, Matono K, Sasatomi T, Ishibashi N, Shida S, Ohkita A, Fukumitu T, Mizobe T, Ikeda S, Ogo S, Ozasa H, Shirouzu K: Oral fluoropyrimidines may not reduce the risk of postoperative recurrence in colorectal cancer associated with mesenteric lymph node metastasis. Int Surg; 2007 Nov-Dec;92(6):314-9
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral fluoropyrimidines may not reduce the risk of postoperative recurrence in colorectal cancer associated with mesenteric lymph node metastasis.
  • To clarify the efficacy and problems of postoperative adjuvant chemotherapy using oral fluoropyrimidines, the clinicopathological data of 307 colorectal cancer patients treated with or without postoperative chemotherapy were analyzed retrospectively.
  • Patients in the chemotherapy group (n=188) who underwent curative resection were followed by administration of oral fluoropyrimidine.
  • The disease-free survival rate in the chemotherapy group was significantly higher than that in the surgery alone.
  • However, no significant difference in disease-free survival rate was found for those with tumors that were associated with mesenteric lymph node involvement and tumors with a high grade of lymphatic invasion or high grade of venous invasion.
  • Postoperative adjuvant chemotherapy using oral fluoropyrimidines such as UFT (litegafur +4:uracil) and 5'-DFUR (doxifluridine) might not reduce the risk of recurrence in colorectal cancer with mesenteric lymph nodes involvement.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / drug therapy. Floxuridine / administration & dosage. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Administration, Oral. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Colectomy. Disease-Free Survival. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mesentery. Middle Aged. Retrospective Studies. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402123.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 039LU44I5M / Floxuridine; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; V1JK16Y2JP / doxifluridine; 1-UFT protocol
  •  go-up   go-down


8. Ma J, Kimura W, Takeshita A, Hirai I, Moriya T, Mizutani M: Neuroendocrine carcinoma of the stomach with peripancreatic lymph node metastases successfully treated with pancreaticoduodenectomy. Hepatogastroenterology; 2007 Oct-Nov;54(79):1945-50
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine carcinoma of the stomach with peripancreatic lymph node metastases successfully treated with pancreaticoduodenectomy.
  • In this report, we described a case of advanced neuroendocrine carcinoma of the stomach with the peripancreatic lymph node metastases which was treated with pancreaticoduodenectomy with extended lymphadenectomy.
  • Computed tomography (CT) showed a large mass in the duodenal bulbus with regional lymph node metastases.
  • The patient's disease was diagnosed as primary duodenal cancer with regional lymph node metastases preoperatively.
  • During the operation, an obviously swollen lymph node on the anterior surface of the head of the pancreas 4.0 x 3.5 cm in size was found growing into the parenchyma of the pancreas head and could not be separated from the pancreas, and the swollen lymph node along the superior mesenteric vein was also hard and suspected to be a metastatic node.
  • The obvious swollen lymph node on the anterior surface of the head of the pancreas and the swollen lymph node along the superior mesenteric vein were also identified as metastatic lymph nodes.
  • Adjuvant chemotherapy with TS-1 was administered on an out-patient basis 6 weeks after the operation.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Duodenum / pathology. Endoscopy, Gastrointestinal. Humans. Immunohistochemistry. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Pancreaticoduodenectomy. Silicates / therapeutic use. Titanium / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251134.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Silicates; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium
  •  go-up   go-down


9. Yasogawa Y, Nishi Y, Kamiya N, Kondo Y, Kaizu T, Hirai T, Tsuchihashi S, Naito M, Idenoue S, Shiraishi H: [A case of advanced gastric cancer with long-term survival treated by S-1/paclitaxel as neo-adjuvant chemotherapy]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1569-71
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with long-term survival treated by S-1/paclitaxel as neo-adjuvant chemotherapy].
  • A 61-year-old male presented with advanced gastric cancer with lymph node swelling around the root of superior mesenteric artery lymph nodes and invasion of pancreas.
  • We thought a complete resection would be difficult, so he was given neo-adjuvant chemotherapy in combination with S-11 20 mg/body/day (3 weeks administration and 1 week rest) and paclitaxel (PTX) 80 mg/m(2) (day 1, 8, 15).
  • After 2 courses of this neo-adjuvant chemotherapy, the tumor and lymph node swelling decreased in size.
  • Total gastrectomy, Roux-en Y and D1+beta type nodal dissection were performed.
  • Intraoperative findings included tumor exposure on the serous membrane and enlarged lymph nodes on the lesser curvature; however, no marked pancreatic invasion was observed and the lymph nodes had become scarred.
  • The changes with neo-adjuvant chemotherapy were judged to be grade 2.
  • After the operation, there was no side effect, though he received the same chemotherapy as an outpatient in three courses.
  • The patient remains alive, and the neo-adjuvant chemotherapy proved effective.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Oxonic Acid / therapeutic use. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Drug Combinations. Gastroscopy. Humans. Male. Middle Aged. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799913.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Tamesa T, Mori N, Okada T, Takemoto N, Sakamoto K, Yamasaki T, Tangoku A, Oka M: [A case of Vp4 hepatocellular carcinoma treated with surgical resection and continuous intrahepatic artery infusion chemotherapy of low-dose cisplatin and 5-fluorouracil]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1769-72
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Vp4 hepatocellular carcinoma treated with surgical resection and continuous intrahepatic artery infusion chemotherapy of low-dose cisplatin and 5-fluorouracil].
  • Portal venous thrombus was observed from the right portal branch to left portal branch and superior mesenteric vein.
  • After chemotherapy, one intrahepatic metastasis appeared and RFA was performed for this tumor.
  • At 16 months after surgery, she had multiple lymph node metastases and died at 20 months after the surgery without intrahepatic metastasis.
  • Low-dose CDDP/5-FU intra-hepatic artery infusion chemotherapy was effective for prevention of intrahepatic recurrence after resection of HCC with portal venous thrombus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hepatectomy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial / methods. Middle Aged. Neoplastic Cells, Circulating / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619515.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


11. Dubernard G, Morice P, Rey A, Camatte S, Pautier P, Lhommé C, Duvillard P, Castaigne D: Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma. Gynecol Oncol; 2005 Apr;97(1):136-41
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma.
  • RESULTS: The overall frequency of lymph node involvement was 63% (12/19).
  • Only 4 patients underwent this procedure as part of their initial surgery (before chemotherapy).
  • When para-aortic nodes were involved, the left para-aortic chain above the level of the inferior mesenteric artery was the site most frequently involved (72%).
  • None of the patients with positive nodes developed recurrent disease in abdominal nodes.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Lymph Nodes / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Paclitaxel / administration & dosage. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790449.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ, Levy A: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg; 2000 Jan;135(1):81-7; discussion 88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
  • HYPOTHESIS: Neoadjuvant therapy has the potential to induce regression of high-risk, locally advanced cancers and render them resectable.
  • Preoperative chemoradiotherapy is proposed as a testable treatment concept for locally advanced pancreatic cancer.
  • A course of chemotherapy with fluorouracil and cisplatin plus radiotherapy was then initiated.
  • Reexploration and resection were planned subsequent to neoadjuvant therapy.
  • INTERVENTIONS: Surgically staged patients with locally advanced pancreatic cancer were treated by preoperative chemotherapy with bolus fluorouracil, 400 mg/m2, on days 1 through 3 and 28 through 30 accompanied by a 3-day infusion of cisplatin, 25 mg m2, on days 1 through 3 and 28 through 30 and concurrent radiotherapy, 45 Gy.
  • RESULTS: Of 14 patients who enrolled in the protocol and were initially surgically explored, 3 refused the second operation and 11 were reexplored; 2 showed progressive disease and were unresectable and 9 (81%) had definitive resection.
  • One patient who was considered too frail for resection had core biopsies of the pancreatic head, node dissection, and an interstitial implant of the tumorous head.
  • Lymph node downstaging occurred in 2 of 4 patients who had positive peripancreatic nodes at the initial surgical staging.
  • In the definitive surgery group the median survival was 19 months after beginning chemoradiotherapy and 16 months after definitive surgery.
  • The absolute 5-year survival was 11% of 9 patients, 1 is surviving 96 months (with no evidence of disease) after chemoradiotherapy and extended pancreatic resection including resection of the superior mesenteric artery and the portal vein for stage III cancer.
  • [MeSH-major] Neoadjuvant Therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / pathology. Radiotherapy Dosage. Reoperation. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10636353.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


13. Turner RR, Nora DT, Trocha SD, Bilchik AJ: Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes. Arch Pathol Lab Med; 2003 Jun;127(6):673-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes.
  • CONTEXT: Nodal staging accuracy is important for prognosis and selection of patients for chemotherapy.
  • Sentinel lymph node (SLN) mapping improves staging accuracy in breast cancer and melanoma and is being investigated for colorectal carcinoma.
  • DESIGN: Sentinel lymph nodes were identified with a dual surgeon-pathologist technique in 51 colorectal carcinomas and 12 adenomas.
  • The frequency of cytokeratin (CK)-positive cells in mesenteric lymph nodes, both SLN and non-SLN, was determined along with their immunohistochemical characteristics.
  • RESULTS: The median number of SLNs was 3; the median number of total nodes was 14.
  • CONCLUSIONS: Sentinel lymph node staging with CK-immunohistochemical analysis for colorectal carcinomas is highly sensitive for detection of nodal tumor cells.
  • [MeSH-major] Colorectal Neoplasms / chemistry. Colorectal Neoplasms / pathology. Keratins / analysis. Lymph Nodes / pathology
  • [MeSH-minor] Adenoma / chemistry. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Colectomy. Databases, Factual. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Sentinel Lymph Node Biopsy / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12741889.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA090848
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


14. Tsioulias GJ, Wood TF, Spirt M, Morton DL, Bilchik AJ: A novel lymphatic mapping technique to improve localization and staging of early colon cancer during laparoscopic colectomy. Am Surg; 2002 Jul;68(7):561-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Encouraging results from our previous studies of sentinel lymph node (SLN) mapping in colorectal cancer (CRC) prompted investigation of its feasibility and accuracy during laparoscopic colectomy for early CRC.
  • All lymph nodes were examined by hematoxylin and eosin (H&E) staining; in addition each SLN was subjected to focused examination by multisectioning and immunohistochemical staining using cytokeratin antibody.
  • In all 14 patients the primary neoplasm and an SLN were identified laparoscopically.
  • An average of 13.5 total lymph nodes and 1.7 SLNs per patient were identified.
  • In four cases with unexpected lymphatic drainage, the extent of mesenteric resection was altered.
  • Lymphatic mapping caused no complications and added only 10 to 15 minutes to the overall operative time.
  • These preliminary findings indicate that colonoscopic/laparoscopic SLN mapping during laparoscopic colon resection is a feasible and technically simple means of identifying the primary colorectal neoplasm and its SLN.
  • Focused pathologic examination of this node can upstage CRC and thereby may improve selection of patients for adjuvant chemotherapy.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Laparoscopy. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12132733.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Kurahara H, Shinchi H, Maemura K, Mataki Y, Aoki M, Sakoda M, Ueno S, Natsugoe S, Takao S: [A case of curatively resected locally advanced pancreatic cancer after chemoradiation therapy]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1983-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of curatively resected locally advanced pancreatic cancer after chemoradiation therapy].
  • A 68-year-old man admitted for pancreatic tumor detected by US was found by computed tomography(CT)to have locally advanced pancreatic cancer invading the portal vein and neural plexus of the superior mesenteric artery without distant metastasis.
  • We conducted preoperative chemoradiation therapy containing S-1 and hyperfractionated accelerated radiation therapy (50 Gy).
  • Reevaluation of CT after chemoradiation therapy showed that the primary tumor reduced 52% without distant metastasis.
  • Extrapancreatic nerve plexus invasion and lymph node metastasis were not observed.
  • The postoperative course was uneventful, and adjuvant chemotherapy (S-1) was started.
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Humans. Male. Neoplasm Staging. Oxonic Acid / therapeutic use. Tegafur / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948269.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


16. Matsukawa H, Shiozaki S, Takakura N, Aoki H, Fujiwara Y, Ohno S, Ojima Y, Harano M, Nishizaki M, Choda Y, Ninomiya M: [A 6-year survival case of locally advanced unresectable pancreatic tail cancer treated with chemo-radiation therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2355-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A 6-year survival case of locally advanced unresectable pancreatic tail cancer treated with chemo-radiation therapy].
  • We report a case of locally advanced unresectable pancreatic tail cancer patient who survived over 6 years by chemo-radiation therapy (CRT).
  • A 61-year-old male was pointed out by CT to have pancreatic tail cancer of 5.6 cm in diameter that invaded to the stomach, left kidney and adrenal gland, nerve plexus of celiac and superior mesenteric artery, was diagnosed as locally advanced unresectable pancreatic tail cancer.
  • After 4 years and 5 months, paraaortic lymph node metastasis was enlarged, so chemotherapy was changed to combination of GEM + S-1.
  • After 4 years and 10 months, upper mediastinal lymph node metastasis appeared.
  • Finally, 6 years and 6 months after the first diagnosis, he died of pancreatic cancer.
  • In the case of pancreatic cancer that CRT is effective to the remission of primary lesion, CRT is potentially useful to perform for the control of metastatic lesion or palliative therapy.
  • [MeSH-major] Pancreatic Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Drug Combinations. Fatal Outcome. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Oxonic Acid / therapeutic use. Palliative Care. Tegafur / therapeutic use

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224571.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


17. Mizuuchi Y, Anbe K, Yamagata N, Ohji Y, Kanamoto K, Yao T: [A case of stage IVb small cell carcinoma of the esophagus obtained prolonged survival after combined modality therapy]. Gan To Kagaku Ryoho; 2010 Apr;37(4):715-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IVb small cell carcinoma of the esophagus obtained prolonged survival after combined modality therapy].
  • A computer tomography scan revealed solitary liver metastasis, and lymph node swelling on the left side of the superior mesenteric artery.
  • So, we started chemotherapy with VP-16 and CDDP, according to a regimen for small cell carcinoma of the lung.
  • After 4 courses of chemotherapy, the primary lesion, liver metastasis, and lymph node swelling had disappeared, so we decided it was a complete response.
  • The patient received 60 Gy radiotherapy in total, and is still alive 6 years after diagnosis without any evidence of recurrence.
  • [MeSH-major] Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Biopsy. Combined Modality Therapy. Esophagoscopy. Female. Humans. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414033.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Deffieux X, Morice P, Thoury A, Camatte S, Duvillard P, Castaigne D: Anatomy of pelvic and para-aortic nodal spread in patients with primary fallopian tube carcinoma. J Am Coll Surg; 2005 Jan;200(1):45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To describe characteristics of patients with nodal spread and the anatomy of pelvic and para-aortic node involvement in primary fallopian tube carcinoma.
  • Initial lymphadenectomy (without chemotherapy) was performed in 6 patients and in 13 patients lymphadenectomies were performed after chemotherapy at the time of second-look operation.
  • RESULTS: Nine patients had nodal involvement: four in the pelvic area and eight in the para-aortic nodes.
  • When para-aortic nodes were involved, the left para-aortic chain above the level of the inferior mesenteric artery was the site most frequently involved (six patients).
  • CONCLUSIONS: In patients with primary tubal carcinoma, the left para-aortic chain above the level of the inferior mesenteric artery is the most frequently involved.
  • [MeSH-major] Carcinoma / secondary. Fallopian Tube Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aorta, Abdominal. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Pelvis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15631919.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Nahas CS, Akhurst T, Yeung H, Leibold T, Riedel E, Markowitz AJ, Minsky BD, Paty PB, Weiser MR, Temple LK, Wong WD, Larson SM, Guillem JG: Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol; 2008 Mar;15(3):704-11
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation.
  • Choice of optimal treatment--neoadjuvant chemoradiation versus systemic chemotherapy alone--depends on accurate assessment of distant disease.
  • We prospectively evaluated the ability of [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) to detect distant disease in patients with locally advanced rectal cancer who were otherwise eligible for combined modality therapy (CMT).
  • Sites other than the rectum, mesorectum, or the area along the inferior mesenteric artery were considered distant and were divided into nine groups: neck, lung, mediastinal lymph node (LN), abdomen, liver, colon, pelvis, peripheral LN, and soft tissue.
  • Confirmation was based on tissue diagnosis, surgical exploration, and subsequent imaging.
  • Greatest accuracy was demonstrated in detection of liver (accuracy = 99.9%, sensitivity = 100%, specificity = 98.8%) and lung (accuracy = 99.9%, sensitivity = 80%, specificity = 100%) disease; PET detected 11/12 confirmed malignant sites in liver and lung.
  • All 10 were correctly staged by pre-CMT PET; abdominopelvic computed tomography (CT) scans accurately detected nine of them.
  • PET may play a significant role in defining extent of distant disease in selected cases, thus impacting the choice of neoadjuvant therapy.
  • [MeSH-major] Neoplasms, Multiple Primary / radionuclide imaging. Positron-Emission Tomography. Rectal Neoplasms / radionuclide imaging. Rectal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Staging. Prospective Studies. Single-Blind Method

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Surg Oncol. 2008 Apr;15(4):1265. Leibold, Tobias [added]
  • (PMID = 17882490.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / R01 82534-01
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


20. Baulieux J, Delpero JR: [Surgical treatment of pancreatic cancer: curative resections]. Ann Chir; 2000 Sep;125(7):609-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of pancreatic cancer: curative resections].
  • [Transliterated title] Traitement chirurgical du cancer du pancréas: les exérèses à visée curative.
  • Lymph node and/or vascular involvement and retroperitoneal tissue invasion constitute very poor prognostic factors; however, lymph node involvement limited to the first draining nodes and limited invasion of the mesenteric-portal vein do not constitute contraindications to surgical resection.
  • Cephalic pancreaticoduodenectomy is still the reference procedure and its postoperative mortality has greatly decreased.
  • Concomitant or neoadjuvant chemotherapy-radiotherapy, currently under evaluation, may increase resection and survival rates.
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Postoperative Complications. Prognosis. Radiotherapy, Adjuvant. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11051689.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 54
  •  go-up   go-down


21. Ando K, Shimamoto T, Hayashi S, Ito Y, Kawanishi Y, Miyazawa K, Kimura Y, Serizawa H, Ebihara Y, Ohyashiki K: [Diffuse large B-cell lymphoma showing CNS invasion by CD30-positive multinuclear giant cells mimicking the clinical features of progressive multifocal leukoencephalopathy]. Rinsho Ketsueki; 2000 Jun;41(6):507-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Southern blot analysis of DNA extracted from the ascites revealed IgJH rearrangement, and therefore she was initially diagnosed as B-cell neoplasia.
  • She received combined chemotherapy (DICE and CHOP regimens), and achieved a transient clinical response.
  • Three months later, she developed various neurological abnormalities, and brain magnetic resonance imaging revealed diffuse infiltration of the cerebral white matter.
  • We considered the possibility of CNS involvement by the lymphoma or progressive multifocal leukoencephalopathy (PML), and began a course of anti-virus therapy and radiation therapy.
  • Because multiple lumbar punctures demonstrated large multinuclear lymphoma cells in the cerebrospinal fluid, a diagnosis of metastatic CNS lymphoma was made.
  • Although the radiation therapy was temporarily effective against the CNS involvement, the patient died of systemic invasion of the lymphoma cells.
  • The final diagnosis was diffuse large B-cell lymphoma on the basis of pathologic findings, immunohistochemistry, and Southern blot analysis using a mesenteric lymph node obtained at autopsy.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Invasiveness


22. Kaku M, Ohara N, Seima Y, Imanishi K, Tomura N, Kobayashi A, Yamasaki M, Hirata Y, Murao S: A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior. Arch Gynecol Obstet; 2004 Dec;270(4):302-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological examination showed a well-differentiated papillary serous cystadenocarcinoma of ovarian type and locoregional lymph node metastases.
  • Seven months after surgery, the patient developed a pelvic recurrence, and underwent a total hysterectomy, a left salpingo-oophorectomy and a resection of the metastatic mesenteric mass.
  • [MeSH-major] Cystadenocarcinoma, Serous / diagnosis. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Carboplatin / therapeutic use. Female. Humans. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Mesentery. Neoplasm Recurrence, Local / surgery. Pelvic Neoplasms / secondary. Taxoids / therapeutic use. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14551796.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down






Advertisement